तुलना करने के लिए मीट्रिक्स | IMNM | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधIMNMपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −11.5x | −5.2x | −0.4x | |
PEG अनुपात | −0.46 | −0.43 | 0.00 | |
क़ीमत/बुक | 4.4x | 1.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 642.0x | 22.0x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | 58.2% | 85.4% | 56.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | 5.2% | 9.1% | अनलॉक करें |
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.